A detailed history of Jennison Associates LLC transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Jennison Associates LLC holds 507,838 shares of VERA stock, worth $10.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
507,838
Previous 813,861 37.6%
Holding current value
$10.6 Million
Previous $34.4 Million 64.56%
% of portfolio
0.01%
Previous 0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 02, 2025

SELL
$24.02 - $43.22 $7.35 Million - $13.2 Million
-306,023 Reduced 37.6%
507,838 $12.2 Million
Q4 2024

Jan 24, 2025

BUY
$38.64 - $49.75 $14.2 Million - $18.2 Million
366,763 Added 82.03%
813,861 $34.4 Million
Q3 2024

Nov 08, 2024

BUY
$34.09 - $46.71 $202,358 - $277,270
5,936 Added 1.35%
447,098 $19.8 Million
Q2 2024

Aug 05, 2024

BUY
$33.72 - $48.82 $12.3 Million - $17.9 Million
366,223 Added 488.69%
441,162 $16 Million
Q1 2024

May 02, 2024

BUY
$14.91 - $49.14 $1.12 Million - $3.68 Million
74,939 New
74,939 $3.23 Million

Others Institutions Holding VERA

About Vera Therapeutics, Inc.


  • Ticker VERA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,042,300
  • Market Cap $565M
  • Description
  • Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...
More about VERA
Track This Portfolio

Track Jennison Associates LLC Portfolio

Follow Jennison Associates LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jennison Associates LLC with notifications on news.